C. R. Bard Receives Fda Premarket Approval Of The Lutonix® 035 Drug Coated Balloon As The First And Only Dcb For The Treatment Of Patients With Dysfunctional Av Fistulae New Option to Preserve Vascular Access and Help Hemodialysis Patients Extend Time Between Reinterventions MURRAY HILL, N.J.–(BUSINESS WIRE)–C. R. Bard, Inc. (NYSE:BCR) today announced the LUTONIX® […]